Adjuvant interferon treatment in human osteosarcoma.
An update of the adjuvant trial on osteosarcoma in Sweden comparing patients receiving natural interferon (IFN) alpha with a high-dose chemotherapy group and a nonadjuvant group is presented. The overall survival for the IFN group is 49%, for the chemotherapy group 54%, and for the nonadjuvant group 35%. Trial evaluation was complicated by group differences with respect to various clinicopathologic features of prognostic significance. The role of IFN in the treatment of osteosarcoma can still not be established.
Strander
H
H
Bauer
H C
HC
Brosjö
O
O
Kreicbergs
A
A
Lindholm
J
J
Nilsonne
U
U
Silfverswärd
C
C
Szamosi
A
A
D001859:Bone Neoplasms / Q000401:mortality / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000627:therapeutic use*; D008727:Methotrexate / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local; D012516:Osteosarcoma / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate
D007155:Immunologic Factors; D016898:Interferon-alpha; D004317:Doxorubicin; D008727:Methotrexate